PA8748501A1 - Uso de agonistas lxr para el tratamiento de la osteoartritis - Google Patents

Uso de agonistas lxr para el tratamiento de la osteoartritis

Info

Publication number
PA8748501A1
PA8748501A1 PA20078748501A PA8748501A PA8748501A1 PA 8748501 A1 PA8748501 A1 PA 8748501A1 PA 20078748501 A PA20078748501 A PA 20078748501A PA 8748501 A PA8748501 A PA 8748501A PA 8748501 A1 PA8748501 A1 PA 8748501A1
Authority
PA
Panama
Prior art keywords
treatment
osteoarthritis
lxr agonists
lxr
agonists
Prior art date
Application number
PA20078748501A
Other languages
English (en)
Inventor
Nagpal Sunil
Yang Zhiyong
Morris Elisabeth
R Lavallie Edward
A Collins-Racie Lisa
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8748501A1 publication Critical patent/PA8748501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN EN LA PRESENTE METODOS DE PREVENCION Y TRATAMIENTO DE LA OSTEOARTRITIS POR MEDIO DE LA UTILIZACION DE AGONISTAS LXR.
PA20078748501A 2006-09-19 2007-09-19 Uso de agonistas lxr para el tratamiento de la osteoartritis PA8748501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84557606P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
PA8748501A1 true PA8748501A1 (es) 2009-07-23

Family

ID=38828649

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078748501A PA8748501A1 (es) 2006-09-19 2007-09-19 Uso de agonistas lxr para el tratamiento de la osteoartritis

Country Status (14)

Country Link
US (1) US20090012053A1 (es)
EP (1) EP2089009A2 (es)
JP (1) JP2010503730A (es)
CN (1) CN101547688A (es)
AR (1) AR062913A1 (es)
AU (1) AU2007297721A1 (es)
BR (1) BRPI0716833A2 (es)
CA (1) CA2662965A1 (es)
CL (1) CL2007002712A1 (es)
MX (1) MX2009002794A (es)
PA (1) PA8748501A1 (es)
PE (1) PE20080908A1 (es)
TW (1) TW200820978A (es)
WO (1) WO2008036239A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102789A2 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteroarthritis
CN102439442A (zh) * 2009-02-02 2012-05-02 雀巢产品技术援助有限公司 用于诊断关节即将衰竭的方法
CN103063840A (zh) * 2011-10-18 2013-04-24 中国科学院武汉病毒研究所 一种细胞靶点肝x受体在制备治疗丙型肝炎病毒药物中的应用
JP6071608B2 (ja) * 2012-03-09 2017-02-01 新日鐵住金ステンレス株式会社 耐酸化性に優れたフェライト系ステンレス鋼板
KR20150040766A (ko) * 2013-10-07 2015-04-15 이화여자대학교 산학협력단 항염증 물질을 스크리닝하는 방법
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
AU2001262984A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1463726A2 (en) * 2001-12-21 2004-10-06 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
WO2003059884A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
EP1480689A1 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
BR0311282A (pt) * 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
BR0314390A (pt) * 2002-09-17 2005-07-19 Pharmacia Corp Moduladores aromáticos dos receptores hepáticos x
US20050036992A1 (en) * 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20050009837A1 (en) * 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
US20060029685A1 (en) * 2004-07-30 2006-02-09 Henderson Todd R Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals
CN101213194A (zh) * 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
WO2006094034A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver x receptor modilators
AU2007217366A1 (en) * 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway

Also Published As

Publication number Publication date
CN101547688A (zh) 2009-09-30
CA2662965A1 (en) 2008-03-27
BRPI0716833A2 (pt) 2013-11-05
EP2089009A2 (en) 2009-08-19
MX2009002794A (es) 2009-03-30
TW200820978A (en) 2008-05-16
US20090012053A1 (en) 2009-01-08
AR062913A1 (es) 2008-12-17
PE20080908A1 (es) 2008-08-21
JP2010503730A (ja) 2010-02-04
WO2008036239A2 (en) 2008-03-27
AU2007297721A1 (en) 2008-03-27
WO2008036239A3 (en) 2008-10-30
CL2007002712A1 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
MY160041A (en) Compositions and methods for treating parasitic infections
PA8748501A1 (es) Uso de agonistas lxr para el tratamiento de la osteoartritis
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
BRPI0807208A2 (pt) Aparelho de iluminação portátil afixável em instrumentos cirúrgicos.
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0718035A2 (pt) Método e disposição para fabricação de metanol
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso